Loading…
Cellebrite DI Ltd. is projected to rise to $17.33 by 2027, a +36% move from its current price of $12.70. CLBT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $12.37 | $12.71 | $13.06 | +0.06% |
| May 30 | $12.24 | $12.71 | $13.21 | +0.11% |
| May 31 | $12.14 | $12.72 | $13.33 | +0.17% |
| Jun 1 | $12.06 | $12.73 | $13.44 | +0.23% |
| Jun 2 | $11.99 | $12.74 | $13.53 | +0.29% |
| Jun 3 | $11.93 | $12.74 | $13.62 | +0.34% |
| Jun 4 | $11.87 | $12.75 | $13.70 | +0.40% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $11.87 | $12.75 | $13.70 | +0.40% |
| Week 2 | $11.57 | $12.80 | $14.16 | +0.81% |
| Week 3 | $11.36 | $12.85 | $14.55 | +1.21% |
| Week 4 | $11.19 | $12.91 | $14.89 | +1.62% |
| Week 5 | $11.04 | $12.96 | $15.20 | +2.03% |
| Week 6 | $10.92 | $13.01 | $15.50 | +2.44% |
| Week 7 | $10.81 | $13.06 | $15.78 | +2.85% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cellebrite DI Ltd. develops software and services for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company provides a platform of software solutions used to access, collect, review, extract, decode, decrypt, analyze, share and manage digital evidence across the investigative lifecycle for a range of investigations, such as child exploitation, homicide, anti-terror, border control, sexual crimes, organized crime, human trafficking, corporate security, and intellectual property theft, as well as financial crimes, including those involving cryptocurrency.
It also offers Inseyets, digital forensics software that collects and reviews digital evidence from various digital sources when conducting legally sanctioned investigations; Guardian Forensics, an evidence management solution which enables customers to manage their digital forensics workflows, and to store, share and review digital evidence; Guardian Collaborate, a digital evidence sharing tool; and Guardian Investigate, a case management and AI-powered analytics solution. In addition, it provides Cellebrite Pathfinder, which reduces the time spent manually reviewing digital evidence and enables actionable insights into a range of crime types; Corellium Falcon for conducting mobile vulnerability research, exploit introspection, and malware analysis; and Corellium Viper for mobile application penetration testing capabilities. Further, the company offers professional services, such as training and certification services, and advanced services.
It serves federal, state, and local agencies, as well as corporations and service providers. The company is headquartered in Petah Tikva, Israel.
Cellebrite DI Ltd. (CLBT) trades at $13.18 with a market capitalization of $3.29B and ranks 1646. The forecast portrays a rising price path through 2050, with a 2026 average of $13.18 and a 2050 average of $78.79, while the 2050 maximum is $147.49. The projected ROI grows from 0% in 2026 to 497.8% by 2050, with bullish sentiment emerging from 2027 onward.
A major floor 13.1% below — a decisive break under it would weaken the trend.
The nearest floor, 4.7% below — buyers have tended to step in here.
The nearest ceiling, 8.7% above — a clean break opens room to run.
A major ceiling 33.9% above — clearing it would confirm fresh momentum.
Key CLBT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CLBT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $13.07 | Sell | $12.98 | Sell |
| MA 10 | $13.06 | Sell | $13.07 | Sell |
| MA 20 | $13.17 | Sell | $13.11 | Sell |
| MA 50 | $13.29 | Sell | $13.42 | Sell |
| MA 100 | $14.28 | Sell | $14.21 | Sell |
| MA 200 | $15.89 | Sell | $15.22 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.53 | Neutral |
| Stoch RSI (14) | 33.50 | Neutral |
| CCI (20) | -96.99 | Neutral |
| Williams %R (14) | -64.91 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -6.75 | Sell |
| Bollinger %B (20,2) | 0.21 | Neutral |
| Stochastic %K (14) | 35.09 | Neutral |
| TRIX (15) | -0.03 | Sell |
| Awesome (5,34) | 0.14 | Buy |
| Ultimate (7,14,28) | 43.68 | Neutral |
| Momentum (10) | -0.04 | Sell |
| Aroon Osc (25) | -16.00 | Sell |
| Hull MA (9) | 12.89 | Sell |
| ADX (14) | 8.02 | Neutral |
| ATR (14) | 0.31 | Info |
Technical picture for the next 30 days shows a neutral setup. RSI14 is 50. The asset trades relative to moving averages with SMA50 at $13.35 and SMA200 at $15.90. Near-term support is at $11.80 and resistance at $13.81. The 30-day price range spans $10.95 to $15.87.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $11.03 | $12.70 | $17.87 | 0% | Neutral | |
| $13.76 | $17.33 | $23.12 | +36% | Bullish | |
| $15.18 | $19.64 | $27.14 | +55% | Bullish | |
| $14.65 | $19.39 | $27.55 | +53% | Bullish | |
| $14.95 | $20.18 | $29.36 | +59% | Bullish | |
| $15.94 | $21.91 | $32.56 | +73% | Bullish | |
| $16.26 | $22.73 | $34.40 | +79% | Bullish | |
| $19.63 | $27.89 | $42.93 | +120% | Bullish | |
| $21.32 | $30.74 | $48.07 | +142% | Bullish | |
| $20.95 | $30.65 | $48.63 | +141% | Bullish | |
| $29.19 | $45.62 | $76.91 | +259% | Bullish | |
| $42.46 | $74.31 | $136.94 | +485% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $11.03 | $12.70 | $14.97 | +0.00% |
| June 2026 | $11.33 | $13.31 | $15.99 | +4.77% |
| July 2026 | $11.30 | $13.38 | $16.30 | +0.57% |
| August 2026 | $11.02 | $13.13 | $16.16 | -1.88% |
| September 2026 | $11.23 | $13.45 | $16.69 | +2.43% |
| October 2026 | $11.57 | $13.93 | $17.42 | +3.59% |
| November 2026 | $11.50 | $13.91 | $17.50 | -0.18% |
| December 2026 | $11.62 | $14.11 | $17.87 | +1.46% |
Click any year to see its month-by-month CLBT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The CLBT price prediction for 2026 points to an average of $12.70 (low $11.03, high $17.87) — a potential gain of 0% on today's $12.70. Price action looks broadly range-bound.
In 2027, CLBT is projected to trade between $13.76 and $23.12, averaging $17.33 — a potential gain of +36% from today's $12.70. That is up +36% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Cellebrite DI Ltd.'s 2028 outlook centres on $19.64, within a $15.18 to $27.14 range. That is up +13% on the projected 2027 average. That marks a +55% change versus current levels. Momentum favours further upside here.
By 2029, CLBT could reach as high as $27.55, with a base case around $19.39 and support toward $14.65 — roughly +53% from $12.70. Buyers look set to stay in control over this stretch.
Expect CLBT to range from $14.95 to $29.36 through 2030. The $20.18 average target implies a +59% move from current prices. That is up +4% on the projected 2029 average. Momentum favours further upside here.
The CLBT price prediction for 2031 points to an average of $21.91 (low $15.94, high $32.56) — a potential gain of +73% on today's $12.70. Buyers look set to stay in control over this stretch.
In 2032, CLBT is projected to trade between $16.26 and $34.40, averaging $22.73 — a potential gain of +79% from today's $12.70. That is up +4% on the projected 2031 average. Momentum favours further upside here.
Cellebrite DI Ltd.'s 2033 outlook centres on $27.89, within a $19.63 to $42.93 range. That is up +23% on the projected 2032 average. That marks a +120% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, CLBT could reach as high as $48.07, with a base case around $30.74 and support toward $21.32 — roughly +142% from $12.70. Momentum favours further upside here.
Expect CLBT to range from $20.95 to $48.63 through 2035. The $30.65 average target implies a +141% move from current prices. That is 0% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
The CLBT price prediction for 2040 points to an average of $45.62 (low $29.19, high $76.91) — a potential gain of +259% on today's $12.70. Momentum favours further upside here.
In 2050, CLBT is projected to trade between $42.46 and $136.94, averaging $74.31 — a potential gain of +485% from today's $12.70. That is up +63% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in CLBT today (≈ 78.740157 CLBT) could be worth
$5,851.46
+$4,851.46 (+485%) by 2050 · US Dollar
Based on the average projected CLBT price of $74.31 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CLBTwould be worth at today's price.
$1,000 invested in CLBT on May 27, 2025 (≈ 58.275059 CLBT) would be worth
$740.09
-$259.91 (-26.0%) today · 0.74× · US Dollar
Based on a CLBT entry price of $17.16 vs. today's $12.7.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $13.4 | $947.76 | -5.2% |
| 1 month ago | $12.66 | $1,003.16 | +0.3% |
| 3 months ago | $13.76 | $922.97 | -7.7% |
| 6 months ago | $16.86 | $753.26 | -24.7% |
| 1 year ago | $17.16 | $740.09 | -26.0% |
| All time (5.0y) ago | $9.89 | $1,284.13 | +28.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CLBT forecast.
Our base-case forecast reaches $25.00 around 2033.
Implied market cap at $25.00: $6.24B
The multi-year forecast indicates a bullish trajectory after a neutral start in 2026. The average price unfolds from 2026 ($13.18) to 2030 ($21.16), 2040 ($47.88), and 2050 ($78.79), with maximums climbing to $147.49 by 2050. The ROI rises from 0% in 2026 to 60.5% in 2030, 263.3% in 2040, and 497.8% in 2050.
The sentiment turns bullish from 2027 onward and remains so through 2050. These are estimates and not guarantees, reflecting potential upside and associated uncertainty.
Tap a question to reveal the answer.
2030 avg price is $21.16, with a min of $15.56 and a max of $31.06. The forecast shows a 60.5% ROI and bullish sentiment.
The 2027–2050 forecasts show rising averages and bullish sentiment, with ROI reaching 38.5% in 2027 and 497.8% by 2050. These are estimates, not guarantees.
Yes. The forecast max values include $51.08 in 2034 and $51.90 in 2035, and $81.81 as the 2040 max, indicating $50 is within the projected range.
Current price is $13.18 and market cap is $3.29B.
RSI14 is 50. SMA50 is $13.35 and SMA200 is $15.90. Support is $11.80 and resistance is $13.81. The 30-day range is $10.95 to $15.87.
Cellebrite DI Ltd. Community Discussion
0Share your Cellebrite DI Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.